Seeking Alpha

Amgen Inc. (AMGN)

()

News & PR
Market Currents

Buzz
Twitter: AMGN

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Outlook for a Merry Christmas Eve

Dec 24 • Philip Davis • 30 Comments
Monday Options Recap

Dec 21 • Frederic Ruffy • Comment!
Equities Update: Stocks Finish Lower as Inflation Signs Emerge

Dec 15 • Midnight Trader • 9 Comments
Our Market Forecast Results - Long and Short Equity Ideas

Dec 15 • Value Expectations • 3 Comments
Will 2009's Losers Become 2010's Winners?

Dec 14 • Alan Brochstein • 6 Comments
8 HealthCare Stocks with 3%+ Dividends

Nov 29 • Hao Jin • 9 Comments
U.S. Healthcare Legislation Investment Impact

Nov 9 • Richard Shaw • 20 Comments
Determining Potential in Health Care Stocks

Oct 30 • J. Royden Ward • 4 Comments
Healthcare Profits: Assessing Company Sensitivity to Obamacare

Oct 30 • Richard Shaw • 11 Comments
Eight Ways to Invest in Cord Blood Industry

Oct 23 • Stockerblog • 9 Comments
Thursday Options Recap

Oct 22 • Frederic Ruffy • Comment!
Thursday Options Update: XRX, SLE, AMGN & ESI

Oct 22 • Andrew Wilkinson • 1 Comment
Report from Europe: Traders are Selling the News

Oct 22 • The Mole • Comment!
Amgen Q3: Beats Nicely, Raises Guidance

Oct 22 • Zacks.com • Comment!
Wall Street Breakfast: Must-Know News

Oct 22 • SA Editor Eli Hoffmann • 11 Comments
Earnings Preview: Amgen

Oct 21 • theflyonthewall.com • Comment!
Report from Europe: A Grounded Boeing to Drag Down the Dow?

Oct 21 • The Mole • 7 Comments
Report from Europe: Stocks up Ahead of Earning Deluge

Oct 19 • The Mole • Comment!
An Earnings Season Options Strategy

Oct 19 • Marco Hickey • 4 Comments
October FDA Calendar Stocks: Tricks or Treats?

Oct 16 • Mike Havrilla • 1 Comment
Biotech: Q3 Market Update

Oct 16 • R. Scott Raynovich • 1 Comment
Amgen Takes on BMY in Battle of the Cancer Antibodies

Sep 25 • EP Vantage • 1 Comment
Amgen's Pipeline Shapes Up

Sep 23 • Zacks.com • Comment!
Investing in the Obesity Drug Basket

Sep 21 • Michael Murphy • 14 Comments
Another Positive Indication for Amgen's Denosumab

Sep 11 • Ketan Desai • Comment!
Ken Griffin's Citadel Fund: Options Eye Candy

Sep 10 • Market Folly • 2 Comments
Closing Update: Stocks String Together 3 Straight Wins, Commodities Gain

Sep 8 • Midnight Trader • 4 Comments
Amgen Is a Healthy Buy - Barron's

Sep 6 • SA Editor Rachael Granby • 5 Comments
Hedge Fund Blue Ridge Concentrates on Apple

Sep 3 • Market Folly • 4 Comments
GARP Filtering Financially Fit Companies

Sep 2 • Richard Shaw • Comment!
Amgen's Kidney Drug Fails

Aug 26 • Zacks.com • 1 Comment
Why Health Insurers Make Lousy Villains

Aug 26 • Rick Newman • 3 Comments
Stocks that Could Benefit from Health Reform

Aug 23 • Zacks.com • 7 Comments
Lilly's Arzoxifene Defeat: Pharma Giant's Pipeline Looks Awfully Dry Now

Aug 20 • EP Vantage • 1 Comment
Inflation Protection: What's Working, What's Not

Aug 18 • Robert Martorana • 10 Comments
3 Biotechs, 3 Big Pharma Plays for the Coming Generics Boom

Aug 18 • The Curious Investor • 4 Comments
Five Stock Ideas in Two Sectors with the Best Outlook

Aug 12 • Robert Martorana • 6 Comments
Cash for Cardiovascular: Who Might Be Next?

Aug 12 • Michael Becker • 1 Comment
Using Put Options to Purchase Big Techs for Less

Aug 6 • Marco Hickey • Comment!
FDA Calendar Updates: Acorda, Amgen

Aug 4 • Mike Havrilla • Comment!
Time to Get Conservative? 50 Ideas for a Summer Sell-Off

Aug 3 • Marco Hickey • 16 Comments

Amgen Inc. (AMGN)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers